As the date draws nearer for a final decision from the FDA on MDMA-assisted therapy, we thought it was a good time to keep hope alive by revisiting the currently-available psychedelic therapeutic: ketamine.
Several new studies have been published since our last webinar on ketamine, and some new formulations have gotten attention as of late, so we wanted to check in with some of those on the front lines of ketamine therapy to find out what practices regarding ketamine therapy are working well and which may not be as effective.
This month we are truly fortunate to have panelists working in ketamine clinics from three different areas of the country discussing a number of topics relevant to the therapeutic use of ketamine, including:
- Advantages of Ketamine (compared to other psychedelics)
- The future landscape of ketamine
- What may happen to ketamine clinics as psychedelics get approved
As always, there will be ample time for audience Q&A, so you’ll get to interact with the panelists directly!
So please join us for this live panel discussion on Thursday, July 25th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterward if you cannot make it to the live event.

